JP2019516979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516979A5 JP2019516979A5 JP2018559227A JP2018559227A JP2019516979A5 JP 2019516979 A5 JP2019516979 A5 JP 2019516979A5 JP 2018559227 A JP2018559227 A JP 2018559227A JP 2018559227 A JP2018559227 A JP 2018559227A JP 2019516979 A5 JP2019516979 A5 JP 2019516979A5
- Authority
- JP
- Japan
- Prior art keywords
- cell concentration
- biological markers
- cancer
- concentration
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 230000033289 adaptive immune response Effects 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102100022790 BTB/POZ domain-containing protein KCTD11 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 102100021186 Granulysin Human genes 0.000 claims 1
- 102100030386 Granzyme A Human genes 0.000 claims 1
- 102100030385 Granzyme B Human genes 0.000 claims 1
- 102100038393 Granzyme H Human genes 0.000 claims 1
- 102100038395 Granzyme K Human genes 0.000 claims 1
- 102100022087 Granzyme M Human genes 0.000 claims 1
- 101000974815 Homo sapiens BTB/POZ domain-containing protein KCTD11 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims 1
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims 1
- 101001033007 Homo sapiens Granzyme K Proteins 0.000 claims 1
- 101000900697 Homo sapiens Granzyme M Proteins 0.000 claims 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101000579218 Homo sapiens Renin Proteins 0.000 claims 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims 1
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100026214 Indian hedgehog protein Human genes 0.000 claims 1
- 101710139099 Indian hedgehog protein Proteins 0.000 claims 1
- 102100022341 Integrin alpha-E Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100028467 Perforin-1 Human genes 0.000 claims 1
- 102100030304 Platelet factor 4 Human genes 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 claims 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 claims 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims 1
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- 206010064390 Tumour invasion Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000009400 cancer invasion Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021188647A JP7654318B2 (ja) | 2016-05-09 | 2021-11-19 | 固形腫瘍を有する患者をクラス分けするための方法 |
| JP2023211166A JP2024019551A (ja) | 2016-05-09 | 2023-12-14 | 固形腫瘍を有する患者をクラス分けするための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305536.1 | 2016-05-09 | ||
| EP16305536 | 2016-05-09 | ||
| PCT/EP2017/061089 WO2017194556A1 (en) | 2016-05-09 | 2017-05-09 | Methods for classifying patients with a solid cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021188647A Division JP7654318B2 (ja) | 2016-05-09 | 2021-11-19 | 固形腫瘍を有する患者をクラス分けするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516979A JP2019516979A (ja) | 2019-06-20 |
| JP2019516979A5 true JP2019516979A5 (enExample) | 2020-05-28 |
| JP7281903B2 JP7281903B2 (ja) | 2023-05-26 |
Family
ID=56014938
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559227A Active JP7281903B2 (ja) | 2016-05-09 | 2017-05-09 | 固形腫瘍を有する患者をクラス分けするための方法 |
| JP2021188647A Active JP7654318B2 (ja) | 2016-05-09 | 2021-11-19 | 固形腫瘍を有する患者をクラス分けするための方法 |
| JP2023211166A Pending JP2024019551A (ja) | 2016-05-09 | 2023-12-14 | 固形腫瘍を有する患者をクラス分けするための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021188647A Active JP7654318B2 (ja) | 2016-05-09 | 2021-11-19 | 固形腫瘍を有する患者をクラス分けするための方法 |
| JP2023211166A Pending JP2024019551A (ja) | 2016-05-09 | 2023-12-14 | 固形腫瘍を有する患者をクラス分けするための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190309369A1 (enExample) |
| EP (1) | EP3455631B1 (enExample) |
| JP (3) | JP7281903B2 (enExample) |
| KR (1) | KR102245021B1 (enExample) |
| CN (2) | CN109690314B (enExample) |
| AU (1) | AU2017261685B2 (enExample) |
| ES (1) | ES2808004T3 (enExample) |
| MX (1) | MX393482B (enExample) |
| PL (1) | PL3455631T3 (enExample) |
| RU (1) | RU2745730C2 (enExample) |
| SG (1) | SG11201809317VA (enExample) |
| WO (1) | WO2017194556A1 (enExample) |
| ZA (1) | ZA201807020B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180357361A1 (en) | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| EP3659110A1 (en) | 2017-07-24 | 2020-06-03 | Ventana Medical Systems, Inc. | Methods and systems for evaluation of immune cell infiltrate in tumor samples |
| DK3746790T3 (da) * | 2018-01-31 | 2023-12-11 | Ventana Med Syst Inc | Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer |
| FR3079617B1 (fr) | 2018-03-29 | 2023-12-22 | Office National Detude Et De Rech Aerospatiales Onera | Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique |
| WO2020245155A1 (en) | 2019-06-03 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for modulating a treatment regimen |
| CN110988324B (zh) * | 2019-11-29 | 2021-08-24 | 广州市雷德医学检验实验室有限公司 | 免疫状态确定系统、方法、装置及存储介质 |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| CN111999503B (zh) * | 2020-05-28 | 2022-05-20 | 首都医科大学附属北京地坛医院 | 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒 |
| EP4172628A1 (en) * | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| CN113174439B (zh) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用 |
| US20240210404A1 (en) * | 2021-04-27 | 2024-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection |
| KR20220155554A (ko) * | 2021-05-13 | 2022-11-23 | 주식회사 센트릭스바이오 | 항-CD300c 항체를 이용한 병용 요법 |
| CA3245129A1 (en) | 2022-03-17 | 2023-09-21 | Univ Paris Cite | METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT |
| EP4533092A1 (en) * | 2022-06-03 | 2025-04-09 | Universita'Degli Studi di Roma "La Sapienza" | Method for determining the prognostic score in patients with metastatic renal carcinoma |
| CN115058504B (zh) * | 2022-07-14 | 2025-07-04 | 广州医科大学 | 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用 |
| CN115747331B (zh) * | 2022-09-22 | 2023-08-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用 |
| TWI826081B (zh) * | 2022-10-28 | 2023-12-11 | 臺北醫學大學 | 癌症進展評估方法及其系統 |
| CN117476097B (zh) * | 2023-10-25 | 2024-06-07 | 中山大学附属第六医院 | 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用 |
| CN119685476A (zh) * | 2024-05-29 | 2025-03-25 | 深圳湾实验室 | 一种与癌症预后相关的基因标志物及其应用 |
| CN119291200A (zh) * | 2024-10-16 | 2025-01-10 | 华中科技大学同济医学院附属协和医院 | 一种用于检测cxcr4+cd8+t细胞用于预测肿瘤免疫治疗的检测试剂盒 |
| CN120259410B (zh) * | 2025-06-05 | 2025-09-23 | 北京大橡科技有限公司 | 基于双Panel多重生物标志物分析的肿瘤免疫响应可能性的评分方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006521562A (ja) * | 2003-03-07 | 2006-09-21 | スレショルド ファーマシューティカルズ インコーポレイティッド | 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法 |
| AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| EP2619576B1 (en) * | 2010-09-24 | 2020-06-10 | Niels Grabe | Means and methods for the prediction of treatment response of a cancer patient |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| EP2805165B1 (en) * | 2012-01-20 | 2018-03-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells |
| AU2013276470B2 (en) * | 2012-06-14 | 2018-06-07 | Assistance Publique Hopitaux De Paris | Method for quantifying immune cells in tumoral tissues and its applications |
| US11242564B2 (en) * | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| EP3470531A1 (en) * | 2012-08-06 | 2019-04-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for screening patients with a cancer |
| HK1211322A1 (en) * | 2013-03-15 | 2016-05-20 | 昂考梅德药品有限公司 | Methods of treating pancreatic cancer |
| WO2015007625A1 (en) * | 2013-07-15 | 2015-01-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
-
2017
- 2017-05-09 CN CN201780028301.7A patent/CN109690314B/zh active Active
- 2017-05-09 ES ES17725195T patent/ES2808004T3/es active Active
- 2017-05-09 AU AU2017261685A patent/AU2017261685B2/en active Active
- 2017-05-09 KR KR1020187035300A patent/KR102245021B1/ko active Active
- 2017-05-09 JP JP2018559227A patent/JP7281903B2/ja active Active
- 2017-05-09 EP EP17725195.6A patent/EP3455631B1/en active Active
- 2017-05-09 RU RU2018143409A patent/RU2745730C2/ru active
- 2017-05-09 MX MX2018013744A patent/MX393482B/es unknown
- 2017-05-09 SG SG11201809317VA patent/SG11201809317VA/en unknown
- 2017-05-09 WO PCT/EP2017/061089 patent/WO2017194556A1/en not_active Ceased
- 2017-05-09 CN CN202210976807.3A patent/CN115198018A/zh active Pending
- 2017-05-09 US US16/099,451 patent/US20190309369A1/en active Pending
- 2017-05-09 PL PL17725195T patent/PL3455631T3/pl unknown
-
2018
- 2018-10-22 ZA ZA2018/07020A patent/ZA201807020B/en unknown
-
2021
- 2021-11-19 JP JP2021188647A patent/JP7654318B2/ja active Active
-
2023
- 2023-12-14 JP JP2023211166A patent/JP2024019551A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516979A5 (enExample) | ||
| RU2018143409A (ru) | Способы классификации пациентов с солидным раком | |
| WO2014009535A3 (en) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes | |
| CN114341367B (zh) | 肺腺癌分子分型及生存风险基因群及诊断产品和应用 | |
| Davar et al. | Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial | |
| EP2982985A1 (en) | System for predicting prognosis of locally advanced gastric cancer | |
| Kanduri et al. | Identification of global regulators of T-helper cell lineage specification | |
| Matsuzaki et al. | β2-Microglobulin is an appropriate reference gene for RT-PCR-based gene expression analysis of hematopoietic stem cells | |
| CN102753704A (zh) | I型干扰素诊断 | |
| AU2020215312B2 (en) | Method of predicting survival rates for cancer patients | |
| US20140303034A1 (en) | Predicting prognosis in classic hodgkin lymphoma | |
| EP2390370A3 (en) | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent | |
| Liu et al. | Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study | |
| US20240093318A1 (en) | Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes | |
| CN115198019A (zh) | 一种与头颈鳞状细胞癌放疗敏感性相关的预后标志物、预后及放疗风险评估方法的应用 | |
| US20100298160A1 (en) | Method and tools for prognosis of cancer in er-patients | |
| Kim et al. | Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin | |
| Leng et al. | A direct plasma miRNA assay for early detection and histological classification of lung cancer | |
| US20230085358A1 (en) | Methods for cancer tissue stratification | |
| JP2025515307A (ja) | 炎症を治療するためのトランスクリプトーム解析 | |
| Hall et al. | QuantiGene Plex represents a promising diagnostic tool for cell-of-origin subtyping of diffuse large B-cell lymphoma | |
| CN113234817B (zh) | 利用CpG位点甲基化水平检测早期肝癌的标志物 | |
| US20190085397A1 (en) | Urine biomarkers for detecting graft rejection | |
| Seo et al. | Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype | |
| US20250140406A1 (en) | Classifying tumors and predicting responsiveness |